Biogen has had a particularly rough year so far. After much anticipation, the company’s Alzheimer's disease drug, Aduhelm was launched amidst huge controversies with respect to its regulatory approval. The drug’s revenues were as low as $0.3 million in the recent quarter with wholesalers reducing inventories on account of lack of clarity on reimbursement. The company’s core portfolio of multiple sclerosis drugs is also witnessing a sharp drop of around 18% in the last quarter given the strong co ....
26 Oct 2021
Biogen Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 10/26
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Biogen Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 10/26
- Published:
26 Oct 2021 -
Author:
Ishan Majumdar -
Pages:
14
Biogen has had a particularly rough year so far. After much anticipation, the company’s Alzheimer's disease drug, Aduhelm was launched amidst huge controversies with respect to its regulatory approval. The drug’s revenues were as low as $0.3 million in the recent quarter with wholesalers reducing inventories on account of lack of clarity on reimbursement. The company’s core portfolio of multiple sclerosis drugs is also witnessing a sharp drop of around 18% in the last quarter given the strong co ....